Ruth C. Rowland-Jones

Ruth C. Rowland-Jones

Auto-generated profile, based on publicly available information

Ruth C. Rowland-Jones

BioPharm Process Research GSK SG1 2NY Stevenage UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2017 in Biotechnology Progress
Verified
Journal Article
Open access
PDF file
RRRuth C. Rowland‐Jones
Ruth C. Rowland‐Jones
FBFrans van Den Berg
Frans van Den Berg
ARAndrew J. Racher
Andrew J. Racher
EMElaine B. Martin
Elaine B. Martin
CJColin Jaques
Colin Jaques
Cell culture process development requires the screening of large numbers of cell lines and process conditions. The development of miniature bioreactor systems has increased the throughput of such studies; however, there are limitations with their use. One important constraint is the limited number of offline samples that can be taken compared to those taken for monitoring cultures in large‐scale bioreactors. The small volume of miniature bioreactor cultures (15 mL) is incompatible with the large sample volume (600 µL) required for bioanalysers routinely used. Spectroscopy technologies may be used to resolve this limitation. The purpose of this study was to compare the use of NIR, Raman, and 2D‐fluorescence to measure multiple analytes simultaneously in volumes suitable for daily monitoring of a miniature bioreactor system. A novel design‐of‐experiment approach is described that utilizes previously analyzed cell culture supernatant to assess metabolite concentrations under various conditions while providing optimal coverage of the desired design space. Multivariate data analysis techniques were used to develop predictive models. Model performance was compared to determine which technology is more suitable for this application. 2D‐fluorescence could more accurately measure ammonium concentration (RMSECV 0.031 g L−1) than Raman and NIR. Raman spectroscopy, however, was more robust at measuring lactate and glucose concentrations (RMSECV 1.11 and 0.92 g L−1, respectively) than the other two techniques. The findings suggest that Raman spectroscopy is more suited for this application than NIR and 2D‐fluorescence. The implementation of Raman spectroscopy increases at‐line measuring capabilities, enabling daily monitoring of key cell culture components within miniature bioreactor cultures. © 2017 American Institute of Chemical Engineers Biotechnol. Prog., 33:337–346, 2017

31 August 2020 in Biotechnology Progress
Verified
Journal Article
Closed access
PDF file
RRRuth C. Rowland‐Jones
Ruth C. Rowland‐Jones
AGAlexander Graf
Alexander Graf
AWAngus Woodhams
Angus Woodhams
PDPaloma Diaz‐Fernandez
Paloma Diaz‐Fernandez
SWSteve Warr
Steve Warr
MHMarek Hoehse
Marek Hoehse

31 October 2018 in Biotechnology Progress
Verified
Journal Article
Closed access
PDF file
RRRuth C. Rowland‐Jones
Ruth C. Rowland‐Jones
CJColin Jaques
Colin Jaques

16 July 2021 in The Analyst
Verified
Journal Article
Open access
PDF file
JBJames W. Beattie
James W. Beattie
RRRuth C. Rowland-Jones
Ruth C. Rowland-Jones
MFMonika Farys
Monika Farys
RTRichard Tran
Richard Tran
SKSergei Kazarian
Sergei Kazarian
BBBernadette Byrne
Bernadette Byrne
Therapeutic monoclonal antibodies (mAbs) are effective treatments for a range of cancers and other serious diseases, however mAb treatments cost on average ∼$100 000 per year per patient, limiting their use. Currently, industry favours Protein A affinity chromatography (PrAc) as the key step in downstream processing of mAbs. This step, although highly efficient, represents a significant mAb production cost. Fouling of the Protein A column and Protein A ligand leaching contribute to the cost of mAb production by shortening the life span of the resin. In this study, we assessed the performance of used PrAc resin recovered from the middle inlet, center and outlet as well as the side inlet of a pilot-scale industrial column. We used a combination of static binding capacity (SBC) analysis and Attenuated Total Reflection-Fourier Transform Infrared (ATR-FTIR) spectroscopy to explore the used resin samples. SBC analysis demonstrated that resin from the inlet of the column had lower binding capacity than resin from the column outlet. ATR-FTIR spectroscopy with PLS (partial least square) analysis confirmed the results obtained from SBC analysis. Importantly, in situ ATR-FTIR spectroscopy also allowed both measurement of the concentration and assessment of the conformational state of the bound Protein A. Our results reveal that PrAc resin degradation after use is dependent on column location and that neither Protein A ligand leaching nor denaturation are responsible for binding capacity loss.

18 March 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
DSDevi Sietaram
Devi Sietaram
PKPavlos Kotidis
Pavlos Kotidis
RRRuth Rowland-Jones
Ruth Rowland-Jones
GFGary Finka
Gary Finka
ALAlexei Lapkin
Alexei Lapkin
This content was removed at the authors' request because some data were released before receiving formal approval.

17 April 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
DSDevi Sietaram
Devi Sietaram
PKPavlos Kotidis
Pavlos Kotidis
RRRuth Rowland-Jones
Ruth Rowland-Jones
GFGary Finka
Gary Finka
ALAlexei Lapkin
Alexei Lapkin
This paper addresses the challenges in cell line development (CLD), the lengthy and ambiguous clone screening in upstream biopharmaceutical production. Typically, only a small subset of the later stages of CLD data is used for manually selecting lead clones. Addressing this issue, we introduce a multivariate data analysis (MVDA) as an automated, data-driven approach that integrates CLD data of all scales and stages, to identify criteria for earlier, more accurate, and efficient selection of high-performing cell lines, as well as providing sophisticated knowledge on the metabolic patterns prevalent in productive, stable cell lines. CLD is a multi-scale screening process from micro-scale single-cell cloning (SSC) and well plates, to minibioreactor (MBR) production runs for screening cell line stability. The MVDA identified which early micro-scale CLD stages and what criteria provide predictive potential for disregarding more cell lines earlier on in CLD, using four historical CLD data of hundreds of CHO clonal cell lines producing three unique target mAbs. Using decision trees, we derived that the SSC and the 6-well scale-up are the most predictive early-CLD stages for cell line performance in the production runs, with generalised thresholds of VCC_(6-well)>38% and q_(p,Beacon)<40% for safely deselecting poor-performing cell lines across various mAb targets. The MVDA also revealed the metabolic patterns typical in highly productive, stable cell lines, which were elevated oxidative metabolism, modified glutamine and ammonium metabolism, and less lactate-induced cell death. Including these metabolic parameters as selection criteria would be novel, demonstrating the enhanced information retrieval the MVDA method offers.